Andrea Chobrutskiy1, Boris I Chobrutskiy1, Saif Zaman1, Monica Hsiang1, George Blanck2,3. 1. Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA. 2. Department of Molecular Medicine, Morsani College of Medicine, University of South, Florida, Tampa, USA. gblanck@usf.edu. 3. Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12901 Bruce B. Downs Bd. MDC7, Tampa, FL, 33612, USA. gblanck@usf.edu.
Abstract
PURPOSE: Immunogenomics and earlier, pioneering studies, particularly by Whiteside and colleagues, have indicated a positive role for B-cells in breast cancer, as well as a positive role for gamma-delta T-cells. However, these studies have been completely limited to assessing breast cancer tumor tissue. METHODS AND RESULTS: Our analyses here has shown that blood-borne T-cell receptor gamma (TRG) chain sequences were associated with greater overall survival, of particular note due to the comparative longevity of primary breast cancer patients, whereby assessments of disease-free, but rarely overall survival parameters are possible. Additional immunogenomics approaches narrowed the overall survival correlations to specific, TRG complementarity determining region-3, amino acid (AA) sequence chemical features, independently of many common, confounding variables in the breast cancer setting, such as estrogen or progesterone receptor status. CONCLUSIONS: These results are discussed in the context of patient age and with regard to potential antigenic targets, based on the chemistry of the TRG CDR3 AA sequences associated with the higher survival rates.
PURPOSE: Immunogenomics and earlier, pioneering studies, particularly by Whiteside and colleagues, have indicated a positive role for B-cells in breast cancer, as well as a positive role for gamma-delta T-cells. However, these studies have been completely limited to assessing breast cancer tumor tissue. METHODS AND RESULTS: Our analyses here has shown that blood-borne T-cell receptor gamma (TRG) chain sequences were associated with greater overall survival, of particular note due to the comparative longevity of primary breast cancerpatients, whereby assessments of disease-free, but rarely overall survival parameters are possible. Additional immunogenomics approaches narrowed the overall survival correlations to specific, TRG complementarity determining region-3, amino acid (AA) sequence chemical features, independently of many common, confounding variables in the breast cancer setting, such as estrogen or progesterone receptor status. CONCLUSIONS: These results are discussed in the context of patient age and with regard to potential antigenic targets, based on the chemistry of the TRGCDR3 AA sequences associated with the higher survival rates.
Entities:
Keywords:
CDR3 chemical features; Cancer patient blood exomes; Gamma-delta T-cells; Immune receptor blood tests for breast cancer prognoses
Authors: Y Sandberg; J Almeida; M Gonzalez; M Lima; P Bárcena; T Szczepañski; E J van Gastel-Mol; H Wind; A Balanzategui; J J M van Dongen; J F San Miguel; A Orfao; A W Langerak Journal: Leukemia Date: 2006-03 Impact factor: 11.528
Authors: Olga V Britanova; Ekaterina V Putintseva; Mikhail Shugay; Ekaterina M Merzlyak; Maria A Turchaninova; Dmitriy B Staroverov; Dmitriy A Bolotin; Sergey Lukyanov; Ekaterina A Bogdanova; Ilgar Z Mamedov; Yuriy B Lebedev; Dmitriy M Chudakov Journal: J Immunol Date: 2014-02-07 Impact factor: 5.422
Authors: Wei Lue Tong; Blake M Callahan; Yaping N Tu; Saif Zaman; Boris I Chobrutskiy; George Blanck Journal: Breast Cancer Res Treat Date: 2018-09-18 Impact factor: 4.872
Authors: C M Parker; V Groh; H Band; S A Porcelli; C Morita; M Fabbi; D Glass; J L Strominger; M B Brenner Journal: J Exp Med Date: 1990-05-01 Impact factor: 14.307
Authors: Brooke E Mcbreairty; Boris I Chobrutskiy; Andrea Chobrutskiy; Etienne C Gozlan; Michael J Diaz; George Blanck Journal: Biomed Rep Date: 2022-06-09